GPhA OUTLINES AGENDA FOR NEW FDA COMMISSIONER

Officials at the GenericPharmaceuticalAssociation (GPhA)are wasting no time inletting incoming FDACommissioner Andrew von Eschenbach, MD, know whatthey will be expecting from him. In a statement welcomingDr. von Eschenbach to the FDA, GPhA President and ChiefExecutive Officer Kathleen Jaeger said that the appointmentof "a permanent commissioner is an absolute necessity at afederal agency that has such a direct impact on the healthand well-being of America's citizens."

Jaeger urged the new FDA chief to move quickly "toappropriately address important issues, such as anabbreviated approval pathway for generic biopharmaceuticals,authorized generics, the timely approval ofgeneric medicines, and increased funding for the Officeof Generic Drugs."